FDA Inspection 1297968 — Sciegen Pharmaceuticals Inc

Sciegen Pharmaceuticals Inc — FEI 3008298016

The FDA completed an inspection of Sciegen Pharmaceuticals Inc on December 19, 2025 in Hauppauge, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
December 19, 2025
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Hauppauge, NY (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)